MedTrace Logo

Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants

NCT06045000 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-05-04

No results posted yet for this study

Summary

The primary objective of this study is to investigate the rate and routes of excretion, including the mass balance, after single oral dose administration of DC-806 containing 3.7 MBq (100 μCi) of \[14C\]-DC-806 in urine and feces.

Conditions

  • Healthy Volunteers

Interventions

DRUG

DC-806

Oral tablets

DRUG

[14C]-DC-806

Oral capsules

Sponsors & Collaborators

  • DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-14
Primary Completion
2023-10-02
Completion
2023-10-02
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06045000 on ClinicalTrials.gov